1. Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). (October 2020) Authors: Do, K.T.; Frej, K.; Bhushan, K.; Pruitt-Thompson, S.; Zheleva, D.; Blake, D.; Chiao, J.; Shapiro, G.I. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗